FDA Authorizes Pfizer Booster Shot for Children Ages 5 to 11 Years
Third shot can be given at least five months after healthy children complete the two-dose vaccine series
Rare Cases of Monkeypox Diagnosed in Britain
None of the individuals had traveled to the African countries where the virus is endemic
mRNA-1273 Induces Stronger Response Than BNT162b2 for Immunosuppressed
Findings seen in immunosuppressed patients with rheumatic and musculoskeletal diseases, solid organ transplant recipients
One in Nine Discharged After COVID-19 Admission Die or Are Readmitted
Higher risk seen for patients who were male, had multiple comorbidities and more previous emergency department visits
Vaccine Effectiveness Modest for Children, Teens During Omicron
BNT162b2 vaccine effectiveness against symptomatic infection modest and declined rapidly, was higher after booster dose in teens
AUA: Pandemic Disruptions Impacted One in Four Prostate, Bladder Cancer Patients
Changes, delays, and cancellation of cancer treatment and ancillary care reported
AUA: Kidney Transplants From COVID-19-Infected Donors Are Safe
Recipient outcomes similar to kidneys from noninfected donors
DDW: Antibiotics Up Risk of Older-Onset Inflammatory Bowel Disease
Findings regardless of antibiotic class and with a dose-response relationship
Inflammation During COVID-19 Hospitalization Linked to Mortality
Elevated C-reactive protein during hospitalization associated with increased mortality risk after recovery from COVID-19
50-µg mRNA-1273 Safe, Effective for Children Aged 6 to 11 Years
Estimated vaccine efficacy with two doses was 88.0 percent against COVID-19 at a time when delta was dominant circulating variant
